Good evening :)
Switch to
Place Order

Divi's Laboratories Ltd

DIVISLAB
Health CareLabs & Life Sciences Services
LargecapWith a market cap of ₹89,560 cr, stock is ranked 59
Low RiskStock is 1.69x as volatile as Nifty
3,381.250.82% (-27.80)
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CareLabs & Life Sciences Services
LargecapWith a market cap of ₹89,560 cr, stock is ranked 59
Low RiskStock is 1.69x as volatile as Nifty

Key Metrics

PE RatioPE RatioPB RatioPB RatioDividend YieldDiv. Yield
30.257.640.89%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
35.904.360.88%

Forecast & RatingsDetailed Forecast 

29%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Divi's Laboratories Limited is an India-based company, which is engaged in manufacturing and sale of active pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl and Vigabatrin. The Company’s subsidiaries include Divi’s Laboratories USA, Inc., (Divi’s USA) and Divi’s Laboratories Europe AG (Divi’s Europe).

Brands

Divi's

Pharmaceutical company

Brands

Divi's

Pharmaceutical company

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Financial TrendFinancial statements 

2019202020212022+5.10+5.58+7.03+9.07+1.35+1.38+1.98+2.96
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Transcript of Analysts/Institutional Investor Meet/Con. Call 
Announced OnNov 14, 2022

Divi's Laboratories Limited has informed the Exchange about Transcript of Analysts/Institutional Investor Meet/Con. Call | Download

Divi's Laboratories Limited has informed the Exchange about Transcript of Analysts/Institutional Investor Meet/Con. Call | Download

Related Party Transaction 
Announced OnNov 14, 2022

Divi's Laboratories Limited has informed the Exchange about related party transaction for the period ended September 2022 | Download

Divi's Laboratories Limited has informed the Exchange about related party transaction for the period ended September 2022 | Download

Cash Dividend 
Ex. DateAug 11, 2022

Final • Div/Share: ₹ 30

See all events